Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

NCT02094521 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
122
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novo Nordisk A/S